Neuroinflammation is characterized by increased glial activation, pro-inflammatory cytokine concentration, blood-brain-barrier permeability, and leukocyte invasion. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. A large body of evidence implicates neuroinflammation as an important component of many neurological diseases. Preclinical and clinical data suggest that neuroinflammation may be a valid drug target for intervention in Alzheimer’s Disease and other neurological diseases.

 

MSD provides solutions to support and simplify your neuroinflammation research needs. We offer singleplex and multiplex assays to measure biomarkers such as CRP, Eotaxin, and MCP-1.